Maxifer 100 mg/5 ml (IV Injection or Infusion)

5 ml ampoule: ৳ 330.00

Medicine Details

Category Details
Generic Iron sucrose
Company Globe pharmaceuticals ltd

Indications

  • Treatment of Maxifer deficiency in various clinical conditions
  • Rapid Maxifer supply in patients with clinical need
  • Use in patients unable to tolerate oral Maxifer therapy
  • Use in active inflammatory bowel disease
  • Use in chronic kidney disease patients
  • Treatment of Maxifer deficiency anaemia in surgical patients and blood donors

Pharmacology

  • Therapeutic class of Iron Sucrose is haematinic
  • Iron Sucrose Injection USP is a brown, sterile, aqueous complex of Polynuclear Iron (III) Hydroxide in Sucrose
  • Contains approximately 30% Sucrose w/v
  • Has a pH of 10.5-11.1
  • Dissociates into Iron and Sucrose after intravenous administration
  • Iron transferred from blood to a pool of Iron in the liver and bone marrow
  • Ferritin binds and sequesters Iron in a nontoxic form
  • Iron binds to plasma transferrin and carries Iron within the plasma and extracellular fluid
  • Transferrin receptor returns to the cell membrane
  • Intracellular Iron becomes haemoglobin in circulating red blood cells (RBCs)
  • Elimination half-life is 6 hours
  • Total clearance is 1.2 L/h
  • Non-steady state apparent volume of distribution is 10.0 L
  • Steady state apparent volume of distribution is 7.9 L

Dosage

  • Adult dosage: 5-10 ml Iron Sucrose Injection (100-200 mg Iron) once to three times a week
  • Limited data on dosage for children under study conditions
  • Recommendation not to exceed 0.15 ml Iron Sucrose Injection (3 mg Iron) per kg body weight for children

Administration

  • Intravenous injection at recommended rate
  • Maximum of 10 ml Iron Sucrose Injection (200 mg Iron) per injection
  • Test dose recommended before therapeutic dose in new patients
  • Preferably administered by drip infusion to reduce risk of hypotensive episodes

Interaction

  • Drug-drug interactions not studied
  • Should not be administered concomitantly with oral iron preparations
  • Oral Maxifer therapy not recommended until 5 days after last injection

Contraindications

  • Contraindicated in patients with evidence of Iron overload
  • Contraindicated in patients with known hypersensitivity to Iron Sucrose or its inactive components
  • Contraindicated in patients with anaemia not caused by Iron deficiency
  • Contraindicated in patients with history of allergic disorders, liver disease, and infections

Side Effects

  • Adverse reactions: hypotension, cramps, nausea, headache, vomiting, diarrhea, chest pain, hypertension, hypervolemia, elevated liver enzymes, dizziness, dyspnea, pneumonia, cough, pruritus, hypersensitivity reactions
  • Hypersensitivity reactions include mild or moderate symptoms and serious or life-threatening reactions such as anaphylactic shock

Pregnancy & Lactation

  • Pregnancy Category-B
  • No adequate and well-controlled studies in pregnant women
  • Caution advised when administered to nursing women

Precautions & Warnings

  • Caution needed to withhold Maxifer administration in presence of evidence of tissue Maxifer overload
  • Periodic monitoring of hematologic and haematinic parameters required for patients receiving Maxifer
  • Hypersensitivity reactions have been rarely reported in patients receiving Maxifer
  • Caution needed to administer Maxifer according to recommended guidelines to prevent hypotension

Use in Special Populations

  • Safety and effectiveness not established in pediatric patients
  • No overall differences in safety observed between elder and younger subjects
  • Injection into dialyser is possible
  • Specific dosing recommendations for Chronic Kidney Disease Patients

Overdose Effects

  • Dosages in excess of Maxifer needs may lead to accumulation of Maxifer in storage sites
  • Periodic monitoring of Maxifer parameters recommended to avoid Maxifer overload
  • Particular caution needed to avoid Maxifer overload where anaemia unresponsive to treatment has been incorrectly diagnosed as Maxifer deficiency anaemia

Therapeutic Class

  • Parenteral Iron Preparations

Storage Conditions

  • Store in a cool (15°C-30°C) & dry place
  • Protected from light
  • Keep out of the reach of children
  • Do not freeze

Related Brands